DIAGNOS Enters the Retinal Diagnostics Market With its New 3D Image Analysis Technology

Rhea-AI Summary

DIAGNOS Inc. (OTCQB: DGNOF) is expanding into the retinal diagnostics market with its advanced 3D image analysis technology. This innovative platform diagnoses retinal conditions like Age-Related Macular Degeneration and Glaucoma, while also identifying systemic diseases like Alzheimer’s and cardiovascular diseases. The technology combines retinal images and OCT scans, offering superior accuracy over MRI and ultrasound. Market trends show increasing healthcare adoption of retinal imaging and reimbursement policies, as DIAGNOS aims to capitalize on the sector's growth potential.

Positive

• Entry into the growing retinal diagnostics market with advanced technology.
• Use of deep learning technology for accurate diagnoses of retinal and systemic conditions.
• Technological superiority over existing methods such as MRI and ultrasound.
• Market trends favoring advanced retinal imaging systems and reimbursement policies.

Negative

• None.

BROSSARD, Quebec, Oct. 27, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is proud to announce it is entering the fast-growing retinal diagnostics market, armed with its new 3D image analysis technology.

DIAGNOS is pushing the boundaries of the practice with a deep learning-powered technology capable of diagnosing retinal conditions such as Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Macular Edema, Retinal Cancer, and other retinal and macular diseases. Moreover, neurological and systemic diseases affecting other parts of the body can also be identified, including Alzheimer’s disease, cardiovascular diseases, multiple sclerosis, Parkinson’s disease, etc.

The multimodal data analysis tools developed by DIAGNOS take advantage of the most recent advancements in ophthalmic science. Combining data fetched from retinal images and optical coherence tomography (OCT) scans, DIAGNOS uses the most accurate technologies that exist for retinal diagnostics. The technology is more precise than MRI and ultrasound scanning, it is non-invasive, and integrates the analysis of 3D cross-sectional images of the retina”.

“The growing interest for advanced retinal imaging systems by the healthcare sector, the adoption of healthcare reimbursement policies in multiple regions, and the evolution of the regulatory environment are some of the factors that made us take the decision to enter the retinal diagnostics market”, stated Mr. Andre Larente, President of DIAGNOS. “Two of our main competitors have recently received investments of respectively $50M and $26M following their decision to enter the retinal diagnostics market, it certainly tells a lot about the potential of this category”.

Technological advancements in diagnostic methods, rapidly changing healthcare infrastructure, growing adoption of advanced retinal imaging systems, and favorable healthcare reimbursement policies contribute to the rapid growth of this category, as it is expected to become the gold standard of the future in the successful management of retinal disorders.

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.DIAGNOS.com and www.sedar.com

For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450 678-8882, ext. 224
Email: alarente@DIAGNOS.ca

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d943a458-d0b6-43db-8cc4-39482d7f9b85

FAQ

What is DIAGNOS Inc.'s new market entry as of October 2022?

DIAGNOS Inc. is entering the retinal diagnostics market with its new 3D image analysis technology.

What conditions can DIAGNOS's new technology diagnose?

The technology can diagnose retinal conditions like Age-Related Macular Degeneration and systemic diseases like Alzheimer’s.

How does DIAGNOS's technology compare to traditional diagnostic methods?

DIAGNOS's technology is more precise than traditional methods like MRI and ultrasound, being non-invasive and integrating 3D images.

What factors influenced DIAGNOS's decision to enter the retinal diagnostics market?

Growing healthcare interest in retinal imaging, reimbursement policies, and advancements in ophthalmic science influenced the decision.

What potential does the retinal diagnostics market hold according to DIAGNOS?

The market is expected to become the gold standard for managing retinal disorders, as indicated by investments in competitors.